Consensus Conference by ILTS:
Thursday, February 7, 2019
Hilton Rotterdam

Transplant oncology is a new concept encompassing multiple disciplines of transplantation medicine and oncology to take hepatobiliary cancer treatment and research to the next level. The Consensus Conference in Rotterdam convened worldwide experts and opinion leaders in transplant surgery, radiology and oncology, hepatology and immunology to discuss the frontiers and future perspectives of multidisciplinary management of hepatobiliary malignancies.

The main topics included liver transplantation for hepatocellular carcinoma, cholangiocarcinoma, colorectal and neuroendocrine liver metastases, pediatric malignancy, therapies for cancer recurrence after liver transplantation and the role of novel chemotherapeutic and biological agents to enhance transplantation outcomes.

After a morning of inspiring lectures, delegates joined afternoon working groups with the task of finding solutions and suggesting guidelines for topic-related issues.

---

The Program

Introductory Lectures (8:00 – 9:30):

• Transplant oncology – Current perspectives
  John Roberts, MD University of California San Francisco – San Francisco, CA, USA
• The future of transplant oncology: Bridging the Gap
  Vincenzo Mazzaferro, MD, Fondazione IRCCS Instituto Nazionale dei Tumori di Milano – Milan, Italy
  Bruno Sangro, MD, PhD The University of Navarra School of Medicine – Pamplona, Spain
• Novel biologic, chemotherapeutic, radiologic, and immunotherapeutic approaches
  R. Mark Ghobrial MD, PhD, FRCS Methodist Hospital – Houston, TX, USA
  Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA

Consensus Conference Lectures (9:30 – 13:00)

• The update of liver transplantation for HCC
  Western experience:
  Francis Yao, MD University of California: San Francisco – San Francisco, CA, USA
  Eastern experience:
  Avi Soin, MD Medanta – The Medicity, India
• The update of liver transplantation for CCA
  Julie Heimbach, MD Mayo Clinic Rochester – Rochester, ME, USA
  Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada
• Emerging indications for liver transplantation: colorectal and neuroendocrine liver metastases
  James Eason, MD Methodist University Transplant – Memphis, TN, USA
  Pal Dag Line, MD, PhD Oslo University Hospital – Oslo, Norway
• Pediatric transplant oncology
  Mohamed Rela, MD, Dr.Rela Institute & Medical Centre – Chennai, India
  Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences – Kumamoto, Japan
• Post-transplant management for cancer recurrence
  Sherrie Bhoori, MD National Cancer Institute – Milan, Italy
  Shusen Zheng, MD, PhD Zhejiang University – Hangzhou, China
• The changes of transplant indications
  DAA therapies
  Marina Berenguer, MD Hospital La Fe – Valencia, Spain
  NASH/HCC
  Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy

Working group discussion (14:00 – 15:30)

1. Liver transplantation for HCC
   – Updates on the selection criteria
   – Prediction models
   – Downstaging and bridging therapies
   – Should small tumors be treated by ablation and reserve OLT for large cancers?
   Group leaders: Vincenzo Mazzaferro, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano – Milan, Italy
   Neil Mehta, PhD University of California: San Francisco – San Francisco, CA, USA
   Avi Soin, MD Medanta – The Medicity, India
   

2. Liver transplantation for CCA /mixed HCC/CCA
   – Hilar CCA
   – Intrahepatic CCA
   – Mixed HCC/CCA (Outcomes, diagnostic and prognostic tools, adjuvant treatments)
   Group Leaders: Julie Heimbach, MD Mayo Clinic Rochester – Rochester, ME, USA
   Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada
   Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA

3. Less common tumors of transplant oncology
   a. Colorectal liver metastasis
   b. Neuroendocrine liver metastasis
   c. Tumors in the pediatric population and other rare tumor
   Group Leaders: Mohamed Rela, MD, Dr.Rela Institute & Medical Centre – Chennai, India
   Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences Kumamoto, Japan
   James Eason, MD Methodist University Transplant – Memphis, TN, USA
   

4. Post-transplant management
   a. Tailored immunosuppression for cancer recipients
   b. Cancer recurrence prediction models and surveillance strategies
   c. New adjuvant therapies for recurrence after OLT (chemotherapy, immunotherapy, new biological treatment and radiotherapy)
   Group Leaders:Marina Berenguer, MD Hospital La Fe – Valencia, Spain
   Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy
   Herold Metselaar, MD, PhD Erasmus MC – Rotterdam, The Netherlands

Working group presentations with statements (16:00 -18:00)

Summary (18:00-18:30)

Download the detailed Program here.

---

CONTINUING MEDICAL EDUCATION (CME) CREDITS

The ILTS 2019 Consensus Conference: Transplant Oncology – The Future of MultidisciplinaryManagement, Rotterdam, Netherlands, 07/02/2019-07/02/2019 has been accredited by theEuropean Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CMEcredits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/sheactually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the AmericanMedical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRACategory 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can befound at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® forECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by theMaintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

---

Ethical MedTech Assessments

ILTS 2019 Consensus Conference: Transplant Oncology – the Future of Multidisciplinary Management is now compliant with the MedTech Europe Code of Ethical Business Practice www.ethicalmedtech.eu.

After rigorous selection, K.I.T. Group GmbH is among the first organisations to earn the Medtech Ethical Charter. This is the official certification of those PCOs that demonstrate understanding and commitment to the new regulations. (https://www.ethicalmedtech.eu/ethical-charter/chartered-organisations/).

Working with K.I.T. Group GmbH, an officially licensed Medtech Trusted Partner, will offer very real advantages to Medtech member companies, medical societies, conference venues and hotels. Read more here.

---

AIFA – The official agency for Italian delegates and industry:

Barbara Mantegazza Aria di Viaggi Srl – Congress and Fair Department
Via Matteo Bandello, 1 – 20123 Milano
P.I. 02818040152 – IATA 38220346
Tel. +39 02.4818691
www.ariadiviaggi.it   
barbara.mantegazza@ariadiviaggi.it

The ILTS Consensus Conference was supported by:

Event Date

February 7, 2019 8:30 am – 6:30 pm

Category

ILTS Events

Venue

Facebook

Twitter

LinkedIn